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INTRODUCTION
Surgery for clinically localized prostate cancer is most effec-
tive when the cancer is organ- or specimen-confined (1). Much
effort has therefore been expended on the accurate preopera-
tive prediction of the final pathologic stage of the tumor, the
single most important prognostic indicator. Using serum
prostate-specific antigen (PSA), biopsy Gleason score and
clinical stage, as well as a variety of other clinical variables
and their combinations, pretreatment nomograms have been
constructed for the prognosis of these tumors (1-9). Although
these nomograms have aided clinicians in counseling patients
and selecting optimal treatment methods, the validity and
general applicability of these tables have been questioned,
especially in regard to their extrapolation to populations and
groups other than those in which the nomograms were orig-
inally constructed (4, 10, 11).
The incidence of prostate cancer in Korean men has been
increasing, necessitating the construction of nomograms
based on Korean data. When compared with age-matched
men in Western countries, Korean men have lower normal
ranges of serum PSA (12) and smaller average prostate gland
volumes. To generate prediction nomograms for Korean men,
we have analyzed prostate cancer data from a single institute
and compared nomograms constructed from these data with
preexisting nomograms (1). Furthermore, we have assessed
the applicability of these nomograms to the Korean popula-
tion and determined the necessity of nomograms based solely
on Korean data.
MATERIALS AND METHODS
A total of 317 Korean men (mean age 64.3 yr, range 40 to
83) with clinically localized prostate cancer who underwent
radical retropubic prostatectomy and bilateral pelvic lym-
phadenectomy at Asan Medical Center between June 1990
and November 2003 were the subjects of this study. Inclu-
sion criteria included a pre-biopsy serum PSA level (Hybritech
Tandem-CIS assay) and transrectal ultrasonography or digital
guided sextant or ten-site prostate needle biopsy and/or trans-
urethral resection of the prostate, with preoperative histologi-
cal grade according to the Gleason histological scoring sys-
tem. Patients who had received any form of neoadjuvant hor-
monal therapy were excluded. Using the preoperative vari-
ables, all patients were assigned a clinical stage in accordance
with the TNM system (1997). 
Radical prostatectomy specimens were examined micro-
scopically in histological sections at multiple levels after rou-
tine fixation. Briefly, each surgical specimen was weighed
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Nomograms for the Prediction of Pathologic Stage of Clinically 
Localized Prostate Cancer in Korean Men
We analyzed the prostate cancer data of 317 Korean men with clinically localized
prostate cancer who underwent radical prostatectomy at Asan Medical Center bet-
ween June 1990 and November 2003 to construct nomograms predicting the patho-
logic stage of these tumors, and compared the outcome with preexisting nomograms.
Multinomial log-linear regression was performed for the simultaneous prediction of
organ-confined disease (OCD), extracapsular extension (ECE), seminal vesicle inva-
sion (SVI) and lymph node metastasis (LNM) using serum prostate-specific antigen
(PSA), Gleason score and clinical stage. Nomograms representing percent proba-
bilities were constructed and compared with those presented by Partin et al. by cal-
culating areas under the receiver operating characteristics (ROC) curves. Median
serum PSA at surgery was 10.8 ng/mL, and median biopsy Gleason score was 7.
Overall OCD, ECE, SVI and LNM rates were 59.6%, 20.5%, 11.7% and 8.2%, respec-
tively, and areas under the curves were 0.724, 0.626, 0.662, and 0.794, respectively.
Pathologic stage of localized prostate cancer in Korean men may be predicted using
the Partin table, with acceptable accuracy for OCD and LNM, but less so for ECE
and SVI.
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and its external surface was covered in India ink before fixing
in 10% formalin. The prostate gland and seminal vesicles
were step-sectioned perpendicular to the apical-basal axis for
examination. Pathological stages were assigned in accordance
with the TNM system (1997). All lymph nodes were analyzed
by routine paraffin sections in addition to previous frozen
sections. Critical pathological parameters considered as diag-
nostic of organ confinement status were extracapsular exten-
sion (ECE), seminal vesicle invasion (SVI) and lymph node
metastasis (LNM). Patients with negative surgical margins,
no ECE, no SVI and no LNM were considered to have organ-
confined disease (OCD).
Using the three preoperative variables, serum PSA, biopsy
Gleason scores and clinical stage, a multinomial log-linear
regression was performed to predict the percent probability of
OCD, ECE, SVI and LNM. The nomograms were constructed
from the predicted percent probabilities at 95% confidence
intervals for the final model. Internal validation was analyzed
from 1000 additional bootstrap samples to determine sensi-
tivity, specificity, positive predictive value and negative pre-
dictive value. For comparison with preexisting nomograms,
receiver-operating-characteristics (ROC) curves were drawn,
and the areas under the curves (AUC’s) were calculated, using
the nomograms presented by Partin et al. (1). All statistical
analyses were performed using SPSS for Windows, version 11.5.
RESULTS
The distribution of the patients and their final pathologi-
cal findings with respect to each clinical parameter are shown
in Table 1. At the time of surgery, the median serum PSA
was 10.8 ng/mL, and the median biopsy Gleason score was 7.
Overall OCD, ECE, SVI and LNM rates were 59.6%, 20.5%,
11.7% and 8.2%, respectively.
Of the 317 patients, 17 (5.4%) had clinical stage T1a or
T1b, 113 (35.6%) had T1c, 183 (57.7%) had T2 and only
4 (1.3%) had T3. Noticeably, all cases of clinical stages T1a
and T1b had OCD. Clinical stage T2a and T2b tumors show-
ed similar findings on all the pathological parameters exam-
ined. OCD in clinical stage T2a and T2b tumors was marked-
ly reduced, to 49.6% and 52.4% respectively, when compared
with the 100.0% and 70.0% observed in stage T1a,b and
T1c tumors (p<0.05). Of the 317 men, 17 (5.4%) had pre-
No. (%) OCD* (%) ECE
� SVI
�(%) LNM
� (%)
Clinical T1a,b 17  (5.4) 17  (100) 0 0 0
stage T1c 113 (35.6) 79 (70.0) 17 (15.0) 9 (8.0) 8 (7.0)
T2a 141 (44.5) 70 (49.6) 37 (26.2) 21 (15.0) 13 (9.2)
T2b 42 (13.2) 22 (52.4) 10 (23.8) 6 (14.3) 4 (9.5)
T3 4 (1.3) 1 (25.0) 1 (25.0) 1 (25.0) 1 (25.0)
PSA
‖ 0-4 17 (5.4) 16 (94.1) 0 1 (5.9) 0
(ng/mL) 4.1-10 125 (39.4) 91 (72.8) 22 (17.6) 10 (8.0) 2 (1.6)
10.1-20102 (32.2) 60 (58.8) 21 (20.6) 12 (11.8) 9 (8.8)
>20 73 (23.0) 22 (30.1) 22 (30.1) 14 (19.2) 15 (20.6)
Gleason  2-4 25 (7.9) 18 (72.0) 5 (20.0) 0 2 (8.0)
score 5-6 101 (31.9) 66 (65.3) 21 (20.8) 12 (11.9) 2 (2.0)
7 98 (30.9) 64 (65.3) 24 (24.5) 6 (6.1) 4 (4.1)
8-10 93 (29.3) 41 (44.1) 15 (16.1) 19 (20.4) 18 (19.4)
Total 317 (100) 189 (59.6) 65 (20.5) 37 (11.7) 26 (8.2)
Table 1. Correlation of clinical parameters with final pathologic
stage
*organ-confined disease, 
� extracapsular extension, 
� seminal vesicle
invasion, 
�lymph node metastasis.
Numbers represent probability (%). Dash (-) represents lack of sufficient data to calculate probability.
Glea-
son
score
Patho-
logi-
cal
stage
Clinical stage
PSA 0-4.0 ng/mL
T1a,b T1c T2a T2b T3
PSA 4.1-10.0 ng/mL
T1a,b T1c T2a T2b T3
PSA 10.1-20.0. ng/mL
T1a,b T1c T2a T2b T3
PSA 20.1- ng/mL
T1a,b T1c T2a T2b T3
2-4      OCD 100 - 99.99 99.99 -- 87.59 77.41 83.80 -- 76.63 64.91 - 35.34 - 46.54 31.53 40.79 -
ECE 0 - 00 -- 10.11 21.05 14.53 -- 11.12 22.88 - 51.00 - 26.85 45.02 42.37 -
SVI 0 - 00 -- 000-- 00 - 0 - 000-
LNM 0 - 0.01 0 -- 1.02 1.26 0.75 -- 9.39 9.90 - 15.42 - 23.00 21.14 14.05 -
5-6      OCD 100 90.41 85.35 --100 81.01 65.88 72.18 -- 70.75 54.25 61.45 -- 40.66 22.38 30.49 -
ECE 0 0 0 -- 0 13.15 23.70 17.56 -- 14.09 25.70 20.47 -- 32.11 44.61 39.37 -
SVI 0 9.59 14.62 -- 0 6.09 9.22 8.50 -- 10.49 14.87 15.39 -- 18.51 24.08 23.20 -
LNM 0 0 0 -- 0 0.32 0.35 0.21 -- 2.93 3.24 1.48 -- 4.79 5.22 2.96 -
7         OCD 100 95.29 91.40 --100 83.07 68.39 75.44 -- 73.10 56.98 65.77 - 100 41.26 24.62 30.86 -
ECE 0 0 0 -- 0 12.68 25.99 20.05 -- 16.03 28.84 23.74 - 0 35.09 50.84 48.51 -
SVI 0 -- -- 0 2.68 4.13 3.38 -- 4.57 7.10 6.24 - 0 9.62 11.43 14.58 -
LNM 0 0 0 -- 0 0.46 0.61 0.25 -- 4.31 5.50 2.63 - 0 11.12 9.72 4.51 -
8-10    OCD 100 - 57.41 -- - 73.85 57.54 63.05 - 100 50.14 35.29 45.44 30.58 99.9918.16 11.52 17.67 5.75
ECE 0 - 0 -- - 10.46 18.3 14.36 - 0 9.55 15.98 14.55 9.41 0 14.91 22.02 23.14 9.54
SVI 0 - 42.56 -- - 11.40 17.25 16.55 - 0 14.14 20.83 22.99 34.05 0 21.37 28.45 30.79 26.05
LNM 0 - 0.02 -- - 3.63 4.44 2.45 - 0 24.28 24.43 14.60 20.53 0.0143.75 36.68 25.19 45.85
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operative serum PSA levels of 4.0 ng/mL or less, a value gen-
erally considered the normal cutoff; 16 of these 17 patients
(94.1%) had OCD. In addition, 125 patients (39.4%) had
preoperative serum PSA levels between 4.1 and 10.0 ng/mL,
102 (32.3%) between 10.1 and 20.0 ng/mL and 73 (23.0%)
higher than 20.0 ng/mL. Gleason scores below 7 were observ-
ed in 126 (39.8%) of the 317 patients, whereas 98 (30.9%)
had Gleason scores of 7 and 93 (29.3%) had Gleason scores
higher than 7.
The results of the multinomial log-linear regression anal-
ysis to predict the final pathologic stage from the patients’
clinical parameters are shown in Table 2. Numbers represent
probability (%) and the dash (-) represents lack of sufficient
data to calculate probability. From the internal validation
analysis, our model predicted the probability of OCD to 69.6
%, ECE to 75.8%, SVI to 86.2% and LNM to 93.2%. Table
3 shows the sensitivity, specificity, positive predictive value
and negative predictive value achieved for various predicted
probability cutoff values for OCD when assessed in the 1000
validation bootstrap samples.
When the AUCs were calculated using the Partin table,
they were found to be 0.724, 0.626, 0.662 and 0.794 for
OCD, ECE, SVI and LNM, respectively (Fig. 1-4).
Probability Sensitivity (%) Specificity (%)
Positive predictive
value (%)
Negative predictive
value (%)
≥0.10 100 (100-100) 0.667 (0-0.759) 55.59 (50.663-59.196) 100 (100-100)
≥0.15 99.425 (98.797-100) 8.333 (5.027-11.655) 57.46 (52.622-61.211) 90.909 (79.167-100)
≥0.20 98.319 (97.102-99.713) 13.194 (8.948-16.911) 58.521 (53.445-62.493) 85.714 (74.425-97.222)
≥0.25 97.826 (96.662-99.462) 18.794 (14.031-23.574) 60.068 (55.286-64.411) 87.689 (79.071-96.875)
≥0.30 94.118 (91.727-96.528) 31.772 (25.445-37.239) 63.296 (58.229-67.366) 81.034 (71.363-88.767)
≥0.35 90.909 (87.744-94.56) 42.282 (36.525-48.394) 66.255 (61.245-70.539) 78.75 (72.981-86.499)
≥0.40 88.494 (85.085-93.156) 47.917 (41.724-54.31) 67.841 (63.123-72.54) 76.923 (70.701-85.541)
≥0.45 82.632 (78.376-87.808) 55.556 (49.966-62.053) 69.953 (65.196-74.638) 71.845 (65.277-79.407)
≥0.50 81.215 (76.754-86.253) 55.556 (49.966-62.053) 69.598 (64.691-74.221) 70.27 (63.578-77.391)
≥0.55 64.327 (59.065-69.684) 71.329 (65.421-76.99) 73.62 (68.793-78.22) 61.714 (56.362-68.048)
≥0.60 62.162 (56.802-68.002) 71.803 (66.039-77.259) 73.214 (68.36-77.884) 60.459 (55.189-66.677)
≥0.65 51.397 (45.781-57.202) 79.137 (73.623-84.796) 75.41 (69.8-81.123) 56.699 (51.506-62.376)
≥0.70 42.708 (37.641-48.449) 87.013 (82.83-90.831) 80.094 (73.735-86.146) 54.902 (50.231-60.182)
≥0.75 33.523 (28.022-39.147) 90.441 (87.103-93.911) 81.429 (74.693-87.903) 52.282 (47.732-57.354)
≥0.80 29.041 (23.285-33.629) 94.326 (91.514-97.121) 86.441 (79.311-92.885) 51.654 (47.296-56.742)
≥0.85 14.286 (10.39-18.373) 99.333 (99.241-100) 96.552 (94.701-100) 48.247 (44.324-53.325)
≥0.90 11.86 (8.274-15.706) 100 (100-100) 100 (100-100) 47.69 (43.829-52.626)
≥0.95 7.272 (4.282-10.226) 100 (100-100) 100 (100-100) 46.372 (42.721-51.386)
Table 3. Predictive performance (Mean [95% confidence interval]) of organ confined disease nomograms in 1000 validation bootstrap
samples
Fig. 1. Receiver operating characteristics (ROC) curve for organ
confined disease (area under the curves [AUC] 0.724).
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Fig. 2. ROC curve for Extracapsular extension (AUC 0.626).
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DISCUSSION
With increasing incidence of prostate cancer, continuing
controversy surrounds the choice of treatment for men with
clinically localized prostate cancer. Although patients with
OCD demonstrate markedly improved disease-free survival
when compared with men with extraprostatic disease (1, 13,
14), the actual rate of OCD, as determined in pathologic spec-
imens at surgery, is reported to be 60% to 70% at best (10).
That is, as many as 30% to 40% of patients with clinically
‘localized’ prostate cancer receive radical operation unneces-
sarily. This situation has prompted efforts to develop methods
for more accurate preoperative prediction of the final patho-
logic stage. In the past decade, many prediction tables and
plots have been generated based on combinations of preoper-
ative parameters (1-5, 8, 15, 16). However, while aiding phy-
sicians in selecting treatment methods, the general applicabil-
ity of these nomograms has been questioned, especially in
regard to their extrapolation to population groups other than
those in which they were generated (4, 10, 11).
The increasing incidence of prostate cancer in Korean men
has raised the same questions to Korean physicians, especially
since Korean patients have clinically distinct characteristics
(12). When compared with Caucasian or Japanese men, age-
matched Korean men have lower normal serum PSA ranges,
and their average total prostate volumes are intermediate
between those of Caucasian and Japanese men. In addition,
Korean men have a lower cancer probability and detection
rate on needle biopsy within the same PSA ranges compared
to Caucasians. Conceivably, these distinctive features may
limit the usefulness of preexisting nomograms, necessitating
verification of their applicability to this population or construc-
tion of prediction tables based on data from Korean men only.
We found that 17 of 317 patients (5.4%) had serum PSA
levels below 4.0 ng/mL, and that 8 of these patients (47.1%)
harbored cancer cells with poor differentiation, as shown by
a Gleason score of 7 or higher. Similarly, 69 of 125 patients
(55.2%) with serum PSA levels between 4.1 and 10.0 ng/mL
had tumors with a Gleason score of 7 or higher, a surprisingly
high proportion considering the low serum PSA levels. Like-
wise, of the 191 patients with a Gleason score of 7 or higher,
77 (40.3%) had serum PSA levels lower than 10.0 ng/mL.
When compared with age-matched Caucasians (1), Korean
men showed a higher OCD rate at all PSA concentrations.
When matched by Gleason score and clinical stage, Korean
men also showed a higher OCD rate, except for those with a
Gleason score between 2 and 4. In addition, when compared
with Caucasian men, Korean men showed a lower ECE rate
at all PSA concentrations, Gleason scores and clinical stages.
In contrast, Korean men showed a higher rate of SVI at all
PSA ranges and clinical stages, as well as an overall lower rate
of LNM. These results indicate that Korean men have a higher
rate of OCD, a lower rate of ECE and LNM, and a higher
probability of SVI than Caucasian men (1). Although Korean
men tend to show a higher probability of OCD, once the dis-
ease extends out it tends to invade into the seminal vesicles
first. This may be due to the biological aggressiveness of the
cancer cells, the relatively smaller volumes of the prostate
gland, or the anatomical relationship between the seminal
vesicles and the gland, which may facilitate cancer progres-
sion at an earlier stage when the tumor mass is smaller.
ROC analyses were performed to assess the discriminative
ability of the Partin tables. A test is generally considered to
have an acceptable discriminative power when the AUCs are
higher than 0.7 on an ROC curve. AUCs regarding OCD
and LNM were 0.724 and 0.794. Thus, despite the apparent
Fig. 3. ROC curve for seminal vesicle invasion (AUC 0.662).
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Fig. 4. ROC curve for lymph node metastasis (AUC 0.794).
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differences in preoperative parameters and pathological stage,
the Partin tables were able to accurately predict OCD and
LNM in Korean men. However, the AUC’s for ECE and SVI
were lower (0.626 and 0.662, respectively), indicating that
the Partin tables are less accurate for predicting ECE and SVI
in Korean men. As previously mentioned, Korean men have
a higher rate of OCD and SVI, but a lower rate of ECE and
LNM, compared to the results of Partin et al. (1), but the dif-
ferences in ECE and SVI were more pronounced than those
in OCD and LNM. This may indicate that the prostate can-
cer characteristics of Korean men are similar to those of Cau-
casian men or that the larger number of cases integrated in the
Partin table contributed to a statistical difference. 
The descriptive cancer statistics presented in this study
provide representative data that illustrate the characteristics
of prostate cancer in Korean men. The prediction nomograms
we have generated will assist physicians in counseling Korean
men with prostate cancer regarding the probability of their
tumor being at a specific pathological stage. Furthermore,
these nomograms will assist doctors and their patients to make
more informed treatment decisions based on pathological
stage, risk tolerance and the values they place on various poten-
tial outcomes. In addition, these nomograms may aid in ratio-
nal selection of patients to undergo radical curative surgery,
specifically in Korean men with clinically localized prostate
cancer. However, it should be remembered that the data in
this study and the nomograms generated come from a single
institute, which may limit the applicability of our results. At
the present time, a larger multi-institutional study is under-
way to generate more accurate and representative results.
In conclusion, nomograms predicting the pathologic stage
of clinically localized prostate cancer in Korean men have been
constructed and validated with accuracy using data from a
single institute. With increasing incidence, these nomograms
may serve a useful tool in making therapeutic decisions for
Korean men with newly diagnosed prostate cancer. A larger
scale, multi-center study with validation test is warranted
for a more representative data. 
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